文献速递慢性肾脏病血液净化与透析

Vadadustat每周三次治疗透析依赖CKD贫血

Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD.
PubMed 文献 · Am J Kidney Dis · 2024-11-07

这项3b期开放标签非劣效试验纳入456例透析依赖CKD贫血患者,随机接受Vadadustat 600mg或900mg每周三次或MPG-EPO治疗。Vadadustat在维持血红蛋白方面非劣于MPG-EPO,不良事件发生率相似。

要点

  • Vadadustat每周三次在血红蛋白变化上非劣于MPG-EPO。
  • Vadadustat组ESA救援需求低于MPG-EPO组。
  • 两组治疗中出现的不良事件和严重不良事件发生率相似。

核心结论

  • 每周三次Vadadustat在血红蛋白水平影响上非劣于MPG-EPO,且未检测到不良事件差异。

研究设计与样本

  • 3b期、开放标签、非劣效试验,在美国多中心纳入456例透析依赖CKD贫血成人患者。

主要发现

  • 合并Vadadustat组(600mg和900mg每周三次,n=304)与MPG-EPO组(n=152)比较,主要终点最小二乘均数治疗差异为-0.33(95%CI -0.53至-0.13),次要终点为-0.33(95%CI -0.56至-0.09)。
  • MPG-EPO组ESA救援更常见(主要评估期27.7%,次要评估期16.2%),合并Vadadustat组分别为14.2%和7.3%。
  • 输血率低且各组相似(合并Vadadustat组2.7%,MPG-EPO组4.0%)。
  • 除Vadadustat 600mg组初始血红蛋白轻微下降并在第12周稳定外,所有组平均血红蛋白浓度稳定。

关键数值与推荐

  • 非劣效性定义为血红蛋白浓度平均变化差异的95%CI下限高于-0.75g/dL。

临床怎么用

  • 对于透析依赖CKD贫血患者,可考虑使用Vadadustat每周三次作为MPG-EPO的替代方案。

局限性

  • 不良事件归因于药物可能存在错误。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may offer an alternative to erythropoiesis-stimulating agents (ESAs) for the treatment of anemia in the setting of chronic kidney disease (CKD). The objective of this study was to investigate the efficacy and safety of conversion from the long-acting ESA methoxy polyethylene glycol-epoetin-ß (MPG-EPO) to the oral HIF-PHI vadadustat 3 times weekly versus maintenance therapy with MPG-EPO. STUDY DESIGN: Phase 3b, open-label, noninferiority trial. SETTING & PARTICIPANTS: Multicenter study in the United States in 456 adult participants with anemia and dialysis-dependent CKD. INTERVENTION: Participants were randomized 1:1:1 to vadadustat at a starting dose of 600mg thrice weekly, vadadustat at a starting dose of 900mg thrice weekly, or MPG-EPO for up to 52 treatment weeks and 4 safety follow-up weeks after the end of treatment or early termination. OUTCOMES: Primary and secondary efficacy end points were the mean change in hemoglobin concentration from baseline during primary (weeks 20-26) and secondary (weeks 46-52) evaluation periods, respectively. Noninferiority was specified as a lower bound of the 95% CI above -0.75g/dL for the difference in mean change in hemoglobin concentration from baseline. Other efficacy end points were the proportion of participants with hemoglobin levels within the target range and the proportions of participants requiring ESA or red blood cell transfusion rescue for anemia during the evaluation periods. Primary safety end points were any treatment-emergent and serious adverse events (AEs). RESULTS: After combining the vadadustat groups (600mg and 900mg thrice weekly; n=304), vadadustat was noninferior to MPG-EPO (n=152) for primary (least-squares mean treatment difference, -0.33; 95% CI, -0.53 to-0.13) and secondary (-0.33; -0.56 to-0.09) efficacy end points. Mean hemoglobin concentrations were stable for all groups except for an initial slight decrease in the vadadustat 600mg group, which stabilized by week 12. ESA rescue for anemia was more frequent in the MPG-EPO group (primary evaluation period, 27.7%; secondary evaluation period, 16.2%) than in the combined vadadustat (14.2%; 7.3%) groups. Transfusion rates were low and occurred at similar rates across treatment groups (2.7% and 4.0% in the combined vadadustat and MPG-EPO groups, respectively). The incidences of any treatment-emergent and serious treatment-emergent AEs were similar across treatment groups. LIMITATIONS: Potential errors in attribution of AEs as drug-related. CONCLUSIONS: Three-times-weekly vadadustat was noninferior to MPG-EPO in its effect on hemoglobin levels without detectable differences in AEs. FUNDING: Funding from a private entity (Akebia Therapeutics, Inc). TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study identifier NCT04707768. PLAIN-LANGUAGE SUMMARY: Vadadustat, taken 3 times a week, was noninferior to methoxy polyethylene glycol-epoetin-ß (MPG-EPO) in treating anemia. Vadadustat is an oral drug used to treat anemia in people with chronic kidney disease. This study enrolled participants undergoing dialysis for kidney failure and compared the efficacy and safety of continuing to receive MPG-EPO, a long-acting injectable anemia treatment, or switching to vadadustat, taken by mouth 3 times per week for 1 year. Vadadustat was noninferior to MPG-EPO in maintaining hemoglobin levels. Hemoglobin levels remained stable across all groups, except for a slight decrease in the lower-dose vadadustat group, which stabilized with dose titration by week 12. The occurrence of new or serious side effects was similar across treatment groups.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Toka HR, Bernardo M, Burke SK, et al. Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD. Am J Kidney Dis. 2024. PMID: 39521398. doi:10.1053/j.ajkd.2024.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。